Participant experiences using novel home-based blood collection device for viral load testing in HIV cure trials with analytical treatment interruptions

Figures & data

Figure 1 Experimental blood collection device for home-based viral load testing under development by Tasso, Inc. and Merck & Co, Inc., Kenilworth, NJ, USA.

Table 1 Demographic characteristics of study participants (Philadelphia, PA, United States, 2021–2022).

Tasso participant ID	Gender	Sex assigned at birth	Age	Race	Ethnicity	Education	Timepoint #1	Timepoint #2	Timepoint #3	# At-home blood collections	Comment
Participants from ‘A Phase I Study to Evaluate Innate Activation Predictors of Sustained Viral Control in Adults Living with HIV Undergoing a Brief Analytical Treatment Interruption after the Administration of Pegylated Interferon Alpha 2b in Combination with Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074’ (NCT03588715) (Penn Presbyterian Medical Center)
TASSO-1	M	M	59	Black/African American	Non-Hispanic/Latino	Some College	January 2021	March 2021	September 2021	118
TASSO-2	M	M	58	Black/African American	Non-Hispanic/Latino	2-year degree	January 2021	March 2021	July 2021	92
TASSO-7	M	M	45	Black/African American	Non-Hispanic/Latino	High School Diploma	January 2021	March 2021	April 2021	47
TASSO-8	M	M	31	Other	Hispanic/Latino	2-year degree	February 2021	April 2021	February 2022	164	Post-Intervention Controller
TASSO-9	M	M	M	More than One Race	Non-Hispanic/Latino	Some College	January 2021	March 2021	October 2021	118
TASSO-10	M	M	60	White Caucasian	Non-Hispanic/Latino	High School Diploma	January 2021	March 2021	July 2021	94
TASSO-11	M	M	56	Black/African American	Non-Hispanic/Latino	Some College	January 2021	March 2021	September 2021	122
TASSO-18	M	M	49	More than One Race	Non-Hispanic/Latino	Some College	May 2021	June 2021	July 2021	58
Participants from ‘A Phase I Study to Evaluate Innate Activation Predictors of Sustained Viral Control in Adults Living with HIV Undergoing a Brief Analytical Treatment Interruption after the Administration of Pegylated Interferon Alpha 2 b in Combination with Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074’ (NCT03588715) (Philadelphia FIGHT Community Health Centers)
TASSO-3	W	F	52	Black/African American	Non-Hispanic/Latino	High School Diploma	February 2021	March 2021	November 2021	150
TASSO-4	M	M	52	More than One Race	Non-Hispanic/Latino	2-year degree	January 2021	March 2021	June 2021	86
TASSO-5	M	M	51	Black/African American	Non-Hispanic/Latino	4-year degree	January 2021	March 2021	August 2021	84
TASSO-6	TW	M	54	Black/African-American	Hispanic/Latino	High School Diploma	February 2021	March 2021	July 2021	76
TASSO-20	M	M	37	Black/African American	Non-Hispanic/Latino	High School Diploma	June 2021	July 2021	February 2022	108
Participants from ‘CD4 CAR + Zinc Finger Nuclease (ZFN)-modified T Cells in HIV Therapy’ (NCT03617198) (Hospital of the University of Pennsylvania)
TASSO-12	M	M	60	White/Caucasian	Non-Hispanic/Latino	2-year degree	January 2021	March 2021	February 2022	100	Post-Intervention Controller
TASSO-13	M	M	39	Black/African American	Non-Hispanic/Latino	Some High School/No Diploma	March 2021	April 2021	August 2021	69
TASSO-14	M	M	48	Other	Hispanic/Latino	2-year degree	February 2021	March 2021	Missed Window	8
TASSO-15	M	M	56	Black/African American	Non-Hispanic/Latino	4-year degree	January 2021	June 2021	October 2021	61

M = man/male; F = female; TW = transgender woman.

Figure 2 Summary of ATI participant experiences with home-based blood collection device for viral load testing.

Data availability

All data relevant to this study have been provided in the text and in the Supplementary Appendices.